Lymphadenopathy as a Side Effect of Influenza Infection and Vaccination
Yes, lymphadenopathy can occur as a side effect of both influenza vaccination and influenza infection, though it is relatively uncommon with the vaccine.
Influenza Vaccine-Associated Lymphadenopathy
Lymphadenopathy is a recognized but infrequent adverse effect of influenza vaccination. In a study of 420 healthcare workers who received influenza vaccine, lymphadenopathy was reported in 3.3% of cases 1. Additionally, case reports have documented specific instances of vaccine-induced lymphadenitis, including:
- Regional lymphadenitis: A documented case of supraclavicular lymphadenopathy developing one week after H1N1 vaccination, with pathologic examination showing preserved lymph node architecture with marked immunoblast proliferation 2
- Pediatric cases: A 5-year-old child developed right axillary reactive lymphadenitis following H1N1 vaccination 3
Imaging Considerations
Influenza vaccination can cause FDG-avid lymph nodes on PET/CT imaging, which may persist and create diagnostic challenges. This is particularly important when evaluating patients with cancer or suspected malignancy 4. The imaging findings include:
- Ipsilateral axillary lymph nodes showing FDG activity after deltoid vaccination
- Rare cases of generalized lymph node activation on both sides of the diaphragm, even without tracer accumulation at the vaccination site 4
- Resolution typically occurs within 3 months on follow-up CT imaging 4
Clinical Context from COVID-19 Vaccine Experience
While the question focuses on influenza, the extensive data from COVID-19 vaccines provides relevant context for understanding vaccine-associated lymphadenopathy mechanisms. Lymph node enlargement following vaccination results from locally activated antigens that accumulate at the injection site and migrate to draining nodes 5. The multidisciplinary expert panel notes that multiple reports have found increased nodal and splenic metabolic activity following influenza vaccine on 18FDG-PET 5.
Practical Management Algorithm
For Patients Presenting with Lymphadenopathy After Influenza Vaccination:
Document vaccination details: Specific vaccine type, date of administration, and injection site location
Assess timing: Most vaccine-related lymphadenopathy develops within days to 1 week post-vaccination
Evaluate lymph node characteristics:
- Location (should correspond to drainage pattern from injection site)
- Size, tenderness, and mobility
- Presence of systemic symptoms
If lymphadenopathy persists beyond 3 months: Perform sonographic follow-up examination after an additional 3 months 6
Biopsy indications: Any lymph node that is persistent, progressive in size, or demonstrates suspicious features on imaging should undergo minimally invasive biopsy 6
Critical Pitfalls to Avoid:
- Do not delay cancer staging or treatment for follow-up intervals in patients with confirmed malignancy, regardless of recent vaccination 6
- Always obtain vaccination history before PET/CT imaging to avoid false-positive interpretations 4
- Consider vaccine-related immune response even when generalized FDG-avid lymphadenopathy is present without evidence of tracer activity at the vaccination site 4
Influenza Infection-Associated Lymphadenopathy
While the provided evidence focuses primarily on vaccine-related lymphadenopathy, influenza infection itself can cause reactive lymphadenopathy as part of the systemic immune response to viral infection. This would be expected to occur in the context of active influenza symptoms (fever, myalgia, respiratory symptoms) and resolve with the infection.